景峯醫藥(000908.SZ)第三季度預虧5600萬至7700萬元
格隆匯10月14日丨景峯醫藥(000908.SZ)公佈,預計2021年前三季度歸屬於上市公司股東的淨利潤1100萬元至1600萬元,同比下降78.90%至85.49%;其中,第三季度歸屬於上市公司股東的淨虧損5600萬元至7700萬元,上年同期虧損6273.82萬元。
報吿期內,公司轉讓江蘇璟澤生物醫藥有限公司部分股權,該股權轉讓確認投資收益約1.51億元;上年同期轉讓海門慧聚藥業有限公司部分股權確認投資收益約2.2億元;上述投資收益均為非經常性損益,業績下降主要受股權轉讓確認投資收益所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.